Beating Scleroderma and Raynaud’s with AI: Microsoft and SRUK team up to advance research

SRUK will be working with Microsoft to develop wearable technology to further our research into the conditions.

Microsoft and Tech Trust have awarded SRUK a spot at an envisioning workshop with one of Microsoft's leading AI partners as part of their 'AI for Good' programme. This will contribute towards the development of wearable technologies, which will support our research projects.

This fantastic achievement means that we will receive expert guidance to support our vital research into Scleroderma and Raynaud's. Through this partnership our research will be driven another step forward and sets a precedent for many more projects to come.

AI technology is an essential tool for resolving healthcare issues and enabling a better quality of life, treatment and diagnosis for people suffering from rare medical conditions such as Scleroderma and Raynaud's.

An example of a project by a medical research charity that has been part of the programme previously, includes Cystic Fibrosis Trust's 'Cracking the cystic fibrosis code' project.

UK charity the Cystic Fibrosis Trust partnered with the Alan Turing Institute (the national institute for data science and artificial intelligence) to use advanced machine learning techniques on UK Cystic Fibrosis Registry data taken from 99% of people diagnosed. From AI analysis of this data, they are able to better spot patterns in behaviour, symptoms and treatment effects.

Along a similar vein, SRUK will utilise our involvement with the programme through developing wearable technologies to support our research projects - an incredibly exciting development in our search to find effective treatments for Scleroderma and Raynaud's and a further step in the direction of finding a cure.

Gaining guidance for our research is vital in our mission of reducing the impact of Scleroderma and Raynaud's on people's lives. We're extremely happy to be able to share this news and hope you are as excited about the future of our research as we are.